As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to ...

Ventyx Biosciences has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion. The San Diego-based ...

Jan 9 (Reuters) - Schrodinger (SDGR.O), opens new tab said on Friday it is collaborating with Eli Lilly (LLY.N), opens new tab to offer the pharmaceutical major's AI-based platform, TuneLab, on its ...

Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech. Elaine Chen covers biotech, co-writes The Readout ...

Texas put its signature on one of its biggest economic development wins yet under a new incentive regime, officially clearing the way for Eli Lilly’s $6.5 billion manufacturing plant in northeast ...

・UBS initiated coverage with a ‘Buy’ rating and set a $1,250 price target, citing confidence in Lilly’s obesity execution. ・The firm said it sees a clear path to obesity-driven growth beyond 2026, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The incentives for Lilly's plant ...

Jan 7 (Reuters) - Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling strong investor demand ...

The acquisition is part of Celltrion's strategy to strengthen its competitiveness and establish a production base within the United States. Celltrion plans to invest up to $482 million in its new ...

On the Jan. 5, 2026, episode of The Morning Filter podcast, Morningstar Chief US Market Strategist Dave Sekera commented on what the Food and Drug Administration’s approval of Novo Nordisk’s NVO ...

In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...